CDMO: Avid Bioservices, Inc. Stock

by  •  • Comments Off on CDMO: Avid Bioservices, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 484.35
Enterprise Value ($M) 877.37
Book Value ($M) 180.17
Book Value / Share 2.84
Price / Book 2.69
NCAV ($M) -171.47
NCAV / Share -2.70
Price / NCAV -2.82

Profitability (mra)
Return on Invested Capital (ROIC) -0.03
Return on Assets (ROA) -0.04
Return on Equity (ROE) -0.09

Liquidity (mrq)
Quick Ratio 0.31
Current Ratio 0.46

Balance Sheet (mrq) ($M)
Current Assets 103.59
Assets 455.23
Liabilities 275.06
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
6 days ago 13G Point72 Asset Management, L.P. 5.10
02-14 13G T. Rowe Price Investment Management, Inc. 6.90 20.64
02-13 13G/A Vanguard Group Inc 5.72 -16.82
01-26 13G/A AltraVue Capital, LLC 4.70 -9.95
01-25 13G/A State Street Corp 7.57 -6.63
01-08 13G/A BlackRock Inc. 8.40 -46.75
01-08 13G/A Integrated Core Strategies (us) Llc 6.70 -7.72

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-24 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 ☐ TRANSITION
2024-04-24 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 ☐ TRANSITION REPORT PURSUANT T
2024-04-24 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)
2024-04-24 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2023 ☐ TRANSITI
2023-12-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2023 ☐ TRANSITION REPORT PURSUANT T
2023-09-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-06-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-01 129,700 938,323 13.82
2024-04-30 166,092 874,968 18.98
2024-04-29 364,602 1,438,183 25.35
2024-04-26 395,130 449,976 87.81

(click for more detail)

Similar Companies
CAPR – Capricor Therapeutics, Inc. CASI – CASI Pharmaceuticals, Inc.
CDIO – Cardio Diagnostics Holdings, Inc. CDTX – Cidara Therapeutics, Inc.
CDXC – ChromaDex Corporation


Financial data and stock pages provided by
Fintel.io